相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存:
5
- 供应商:
西宝生物400-021-8158
- 规格:
96T
Enzyme immunoassay for the quantitative determination of antibodies to Infliximab-biosimilar (Remsima®) in serum and plasma with confirmation.
SHIKARI® Quantitative Antibodies to Infliximab Biosimilar ELISA has been especially developed for the quantitative analysis of antibodies to infliximab biosimilar in serum and plasma samples. This kit is optimized with Remsima®.
Infliximab (Remsima®) was associated to the development of anti- Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remsima®. This might lead to severe complications.This kit can be efficiently used for monitoring anti- Infliximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti- Infliximab antibodies.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Models of Inflammation: Carrageenan Air Pouch
:147–153. Jain, M. and Parmar, H.S. 2011. Evaluation of antioxidative and anti‐inflammatory potential of hesperidin and naringin on the rat air pouch model of inflammation
Immunostaining with Anti-Digoxigenin Alkaline Phosphatase
Ususally 1:1000 (v/v) in PBS. Wash in PBS 2' x3. Equilibrate slides in Buffer 1, RT x 5'. Incubate slides in Blocking Buffer, RT x 30' Incubate with anti-Dig-AP conjugate (1:2000 in Blocking buffer.), 2 hrs. RT, or o.n. at 4ºC.
Immunostaining with Anti-Digoxigenin Alkaline Phosphatase
Ususally 1:1000 (v/v) in PBS. Wash in PBS 2' x3. Equilibrate slides in Buffer 1, RT x 5'. Incubate slides in Blocking Buffer, RT x 30' Incubate with anti-Dig-AP conjugate (1:2000 in Blocking buffer.), 2 hrs. RT, or o.n. at 4ºC.
技术资料暂无技术资料 索取技术资料







